Human Papillomavirus and Cytomegalovirus Therapeutics Industry 2020 Market Size (Volume And Value), And The Segment Markets By Regions, Types, Applications And Companies
About Human Papillomavirus and Cytomegalovirus Therapeutics Market
Human papillomavirus (HPV) and Cytomegalovirus (CMV) therapeutics market report studies current as well as future prospects of the market on a global scale. The global market for HPV therapeutics is segmented by drug class and applications. Various drug classes applied against HPV infections are immunomodulators, keratolytic agents, anti-neoplastic agents, and sinecatechins. The HPV therapeutics market is studied by application segments which include genital warts, genital cancers, epidermodysplasia verriformis, oral papillomas, and others (oropharyngeal cancer, laryngeal papillomatosis and others). The global HPV therapeutics market has been extensively analyzed on the basis of the effectiveness and sales revenue of major drug classes as well as geographic prevalence of various HPV infections.
The global CMV therapeutics market is segmented by drugs and applications. The major drugs prescribed for the treatment of CMV infections are ganciclovir, valganciclovir, foscarnet, and cidofovir. The CMV therapeutics treatment is applied against various CMV infections causing retinitis, pneumonia, gastrointestinal ulcers, encephalitis and others (mouth ulcers, pharyngitis and others).
Get Sample Copy of this report @ http://www.marketresearchreports.biz/sample/sample/244198
Geographically, the HPV and CMV therapeutics market has been categorized into five regions namely, North America, Europe, South America, Asia Pacific, and Rest of the World (ROW). The market size and forecast in terms of USD million for each of these segments has been provided for the period 2012 to 2020, considering 2012 and 2013 as base years. The HPV and CMV therapeutics market report also provides compounded annual growth rate (CAGR %) for each market segment for the forecast period 2014 to 2020.
The report also provides pipeline analysis for HPV and CMV therapeutics market, which includes sales forecast for drug candidates currently under phase III clinical trials, and also mentions other candidates in phase I and phase II trials. The research study explains the competitive scenario in the HPV and CMV therapeutics market through Porter’s Five Forces Analysis. A detailed analysis of various macro as well as micro economic factors driving as well as restraining the growth of this market, in addition to future opportunities, is provided in the market overview section of the report. The report also provides market attractiveness analysis and value chain analysis of the global HPV and CMV therapeutics market. Market share analysis for both HPV and CMV therapeutics market has been included. Furthermore, pricing analysis of therapeutic drugs and costs associated with treatment is also studied in the global HPV and CMV therapeutics market report.
View Report @ http://www.marketresearchreports.biz/analysis/244198
A list of recommendations has been provided to help players establish a strong presence in the market and increase their share. The report also profiles major players in the HPV and CMV therapeutics market on the basis of various attributes such as company overview, financial overview, product portfolio, business strategies and recent developments. Mergers, acquisitions, regulatory approvals and other events have been explained in the company profiles section. Key players profiled in the report include AbbVie, Inc., Actavis plc, Clinigen Group plc, Merck & Co., Inc., Perrigo Company plc, Roche Holdings AG and Valeant Pharmaceuticals International, Inc.
The research methodology was based on primary as well as secondary research. Interviews and discussions with a wide range of key industry participants and opinion leaders revealed the real time market scenario. This primary research represented the bulk of our research efforts, which was further supplemented by extensive secondary research. A bottom-up approach was adopted to arrive at global market shares for 2012 and 2013; while an impact based analysis model was adopted to forecast revenue for each market segment. A review of key players’ product literature, annual reports, and press releases supported the market forecast analysis. The 117 pages global HPV and CMV therapeutics market report describes various market dynamics in 51 figures and charts and 16 tables.
Table of Contents
Chapter 1 Introduction
1.1 Report Description
1.2 Market Segmentation
1.3 Research Methodology
1.4 Assumptions
1.5 List of Abbreviations
Chapter 2 Executive Summary
2.1 Market Snapshot: Global HPV Therapeutics Market
2.2 Market Snapshot: Global CMV Therapeutics Market
2.3 Global HPV and CMV Therapeutics Market Revenue, 2012 – 2020 (USD Million)
Chapter 3 Global HPV and CMV Therapeutics Market Overview
3.1 Market Definition and Overview
3.2 Market Dynamics
3.2.1 Human Papillomavirus (HPV) Therapeutics Market
3.2.1.1 Drivers
3.2.1.1.1 Increasing prevalence of HPV infections in developing and underdeveloped economies is aiding the market growth
3.2.1.1.2 Global Age-specific incidence of cervical cancer
3.2.1.1.3 Severe side-effects of HPV vaccines are restraining the market growth and creating opportunity for therapeutics market
3.2.1.2 Restraints
3.2.1.2.1 Increasing demand for minimally invasive surgical procedures in genital warts treatment
3.2.1.2.2 Lack of awareness in developing areas is declining the diagnostic rates
3.2.1.2.2.1 Annual number of new cases (in thousands) of cervical cancer by age group in developed and developing regions (estimations for 2012)
3.2.1.3 Opportunities
3.2.1.3.1 Opportunity for biologics and drugs with low toxicity and short treatment regime against HPV infections
3.2.1.3.2 Health issues raised against approved vaccines have provided wide range of opportunities for effective and safe vaccines and therapeutics
3.2.2 Cytomegalovirus Therapeutics Market
3.2.2.1 Drivers
3.2.2.1.1 High seroprevalence adding to patient pool for CMV therapeutics market
3.2.2.1.2 High global demand for low-cost generic drugs, especially in low- and middle-income countries in South Latin America and Asia Pacific
3.2.2.2 Restraints
3.2.2.2.1 Decreasing CMV prevalence due to highly actively antiretroviral therapy (HAART) and decreasing transplant procedures
3.2.2.3 Opportunities
3.2.2.3.1 Less competition in pediatric CMV therapeutics and increasing demand for CMV vaccine
3.3 Value Chain Analysis
About us
MarketResearchReports.biz is the most comprehensive collection of market
research reports. MarketResearchReports.Biz services are specially designed to
save time and money for our clients. We are a one stop solution for all your
research needs, our main offerings are syndicated research reports, custom
research, subscription access and consulting services. We serve all sizes and
types of companies spanning across various industries.
Contact
Mr. Nachiket
State Tower
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-621-2074
Website: http://www.marketresearchreports.biz/
E: sales@marketresearchreports.biz
Human papillomavirus (HPV) and Cytomegalovirus (CMV) therapeutics market report studies current as well as future prospects of the market on a global scale. The global market for HPV therapeutics is segmented by drug class and applications. Various drug classes applied against HPV infections are immunomodulators, keratolytic agents, anti-neoplastic agents, and sinecatechins. The HPV therapeutics market is studied by application segments which include genital warts, genital cancers, epidermodysplasia verriformis, oral papillomas, and others (oropharyngeal cancer, laryngeal papillomatosis and others). The global HPV therapeutics market has been extensively analyzed on the basis of the effectiveness and sales revenue of major drug classes as well as geographic prevalence of various HPV infections.
The global CMV therapeutics market is segmented by drugs and applications. The major drugs prescribed for the treatment of CMV infections are ganciclovir, valganciclovir, foscarnet, and cidofovir. The CMV therapeutics treatment is applied against various CMV infections causing retinitis, pneumonia, gastrointestinal ulcers, encephalitis and others (mouth ulcers, pharyngitis and others).
Get Sample Copy of this report @ http://www.marketresearchreports.biz/sample/sample/244198
Geographically, the HPV and CMV therapeutics market has been categorized into five regions namely, North America, Europe, South America, Asia Pacific, and Rest of the World (ROW). The market size and forecast in terms of USD million for each of these segments has been provided for the period 2012 to 2020, considering 2012 and 2013 as base years. The HPV and CMV therapeutics market report also provides compounded annual growth rate (CAGR %) for each market segment for the forecast period 2014 to 2020.
The report also provides pipeline analysis for HPV and CMV therapeutics market, which includes sales forecast for drug candidates currently under phase III clinical trials, and also mentions other candidates in phase I and phase II trials. The research study explains the competitive scenario in the HPV and CMV therapeutics market through Porter’s Five Forces Analysis. A detailed analysis of various macro as well as micro economic factors driving as well as restraining the growth of this market, in addition to future opportunities, is provided in the market overview section of the report. The report also provides market attractiveness analysis and value chain analysis of the global HPV and CMV therapeutics market. Market share analysis for both HPV and CMV therapeutics market has been included. Furthermore, pricing analysis of therapeutic drugs and costs associated with treatment is also studied in the global HPV and CMV therapeutics market report.
View Report @ http://www.marketresearchreports.biz/analysis/244198
A list of recommendations has been provided to help players establish a strong presence in the market and increase their share. The report also profiles major players in the HPV and CMV therapeutics market on the basis of various attributes such as company overview, financial overview, product portfolio, business strategies and recent developments. Mergers, acquisitions, regulatory approvals and other events have been explained in the company profiles section. Key players profiled in the report include AbbVie, Inc., Actavis plc, Clinigen Group plc, Merck & Co., Inc., Perrigo Company plc, Roche Holdings AG and Valeant Pharmaceuticals International, Inc.
The research methodology was based on primary as well as secondary research. Interviews and discussions with a wide range of key industry participants and opinion leaders revealed the real time market scenario. This primary research represented the bulk of our research efforts, which was further supplemented by extensive secondary research. A bottom-up approach was adopted to arrive at global market shares for 2012 and 2013; while an impact based analysis model was adopted to forecast revenue for each market segment. A review of key players’ product literature, annual reports, and press releases supported the market forecast analysis. The 117 pages global HPV and CMV therapeutics market report describes various market dynamics in 51 figures and charts and 16 tables.
Table of Contents
Chapter 1 Introduction
1.1 Report Description
1.2 Market Segmentation
1.3 Research Methodology
1.4 Assumptions
1.5 List of Abbreviations
Chapter 2 Executive Summary
2.1 Market Snapshot: Global HPV Therapeutics Market
2.2 Market Snapshot: Global CMV Therapeutics Market
2.3 Global HPV and CMV Therapeutics Market Revenue, 2012 – 2020 (USD Million)
Chapter 3 Global HPV and CMV Therapeutics Market Overview
3.1 Market Definition and Overview
3.2 Market Dynamics
3.2.1 Human Papillomavirus (HPV) Therapeutics Market
3.2.1.1 Drivers
3.2.1.1.1 Increasing prevalence of HPV infections in developing and underdeveloped economies is aiding the market growth
3.2.1.1.2 Global Age-specific incidence of cervical cancer
3.2.1.1.3 Severe side-effects of HPV vaccines are restraining the market growth and creating opportunity for therapeutics market
3.2.1.2 Restraints
3.2.1.2.1 Increasing demand for minimally invasive surgical procedures in genital warts treatment
3.2.1.2.2 Lack of awareness in developing areas is declining the diagnostic rates
3.2.1.2.2.1 Annual number of new cases (in thousands) of cervical cancer by age group in developed and developing regions (estimations for 2012)
3.2.1.3 Opportunities
3.2.1.3.1 Opportunity for biologics and drugs with low toxicity and short treatment regime against HPV infections
3.2.1.3.2 Health issues raised against approved vaccines have provided wide range of opportunities for effective and safe vaccines and therapeutics
3.2.2 Cytomegalovirus Therapeutics Market
3.2.2.1 Drivers
3.2.2.1.1 High seroprevalence adding to patient pool for CMV therapeutics market
3.2.2.1.2 High global demand for low-cost generic drugs, especially in low- and middle-income countries in South Latin America and Asia Pacific
3.2.2.2 Restraints
3.2.2.2.1 Decreasing CMV prevalence due to highly actively antiretroviral therapy (HAART) and decreasing transplant procedures
3.2.2.3 Opportunities
3.2.2.3.1 Less competition in pediatric CMV therapeutics and increasing demand for CMV vaccine
3.3 Value Chain Analysis
About us
MarketResearchReports.biz is the most comprehensive collection of market
research reports. MarketResearchReports.Biz services are specially designed to
save time and money for our clients. We are a one stop solution for all your
research needs, our main offerings are syndicated research reports, custom
research, subscription access and consulting services. We serve all sizes and
types of companies spanning across various industries.
Contact
Mr. Nachiket
State Tower
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-621-2074
Website: http://www.marketresearchreports.biz/
E: sales@marketresearchreports.biz
Comments
Post a Comment